COVID19
Conditions
Keywords
Nafamostat, proteases, TMPRSS2, covid-19, coronavirus
Brief summary
RACONA is a prospective trial that will test the hypothesis that nafamostat can lower lung function deterioration and need for intensive care admission in COVID-19 patients. Design: Adult hospitalized COVID-19 patients will be randomized in a prospective double-blind randomized placebo-controlled study to test the clinical efficacy of nafamostat mesylate (administered intravenously) on top of best standard of care. Primary outcome measures: the time-to-clinical improvement, defined as the time from randomization to an improvement of two points (from the status at randomization) on a seven category ordinal scale or live discharge from the hospital, whichever comes first.
Detailed description
Purpose: SARS-Cov-2 enters the lung cells by binding to ACE-2 and activating the protease TMPRSS2, which, therefore, can be a target for antiviral treatment. Accordingly, TMPRSS2 inhibitors prevent SARS-CoV cell entry in vitro. The most potent such inhibitors, nafamostat is being used as anticoagulant and anti-pancreatitis agent, and is approved for the treatment of cystic fibrosis as its mucolytic action can prevent lung function deterioration by owering airways infections. RACONA study will test the hypothesize that nafamostat is useful in COVID-19 lung involvement because COVID-19 entails activation of the coagulation cascade, pulmonary embolism, and bacterial superinfections.
Interventions
administered intravenously as a continuous infusion
DRUGPlacebo
administered intravenously as a continuous infusion
Sponsors
Yokohama City University
University of Zurich
University Hospital Padova
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)
Masking description
Randomization will be done with an algorithm tailored to the study design. Investigators and patients will be blinded to the treatment administered.
Intervention model description
Randomized, double blind, placebo-controlled parallel-group trial, on top of best standard of care
Eligibility
Sex/Gender
ALL
Age
18 Years to 85 Years
Healthy volunteers
No
Inclusion criteria
* Hospitalized, COVID-19 positive, between 18 and ≤ 85 years of age; * Signed Inform Consent Form; * Body temperature \> 37.3 ℃; * Oxygenation criterion (any of the following): i) Oxygen saturation ≤94% on Room Air; ii) PaO2/FiO2 ratio ≤300 mmHg but \> 100 mmHg, if patient on supplemental oxygen; iii) SpO2/FiO2\<200 if no arterial blood gas available; * Respiratory rate (RR) ≥ 25 beats/min.
Exclusion criteria
* Pregnant or lactating females; * Unwillingness or inability to complete the study. * Rapidly deteriorating clinical condition or low likelihood to complete the study according to the investigator; * eGFR \< 30 ml/min/m2 assessed with CKD EPI formula; * Current or chronic history of liver disease (Child Pugh score ≥ 10), or known hepatic or biliary abnormalities; * Participation in a clinical trial with an investigational product within the following time period prior to the first dosing day in the current study: 5 half-lives or twice the duration of the biological effect of the investigational product (whichever is longer); * Patients requiring high doses of loop diuretics (i.e. \> 240 mg furosemide daily) with significant intravascular volume depletion, as assessed clinically; * History of allergy; * History of sensitivity to heparin or heparin-induced thrombocytopenia; * Unstable hemodynamics in the preceding 4 hours (SBP \< 90 mmHg, and/or vasoactive agents required); * Hemoglobin \< 7 at time of drug infusion. Transfusion is allowed to increase hemoglobin levels before entry into the study; * Malignancy or any other condition for which estimated 6-month mortality \>50%; * Arterial blood pH less than 7.2; * Known evidence of chronic interstitial infiltration at imaging; * Known hospitalization within the past six months for respiratory failure (PaCO2 \> 50 mmHg or PaO2 \< 55 mmHg, or oxygen saturation \<88% on FiO2 = 0.21); * Known chronic vascular disease resulting in severe exercise restriction (i.e. unable to perform household duties); * Known secondary polycythemia, severe pulmonary hypertension, or ventilator dependency; * Known vasculitis with diffuse alveolar hemorrhage;. * Pre-existing renal failure on hemodialysis or peritoneal dialysis requiring renal replacement therapy; * Extracorporeal membrane oxygenation (ECMO); * Immunosuppressive treatment; * Patient in trials for COVID-19 within 30 days before; * Unstable hemodynamics in the preceding 4 hours (MAP ≤ 65 mmHg, or SAP \< 90 mmHg, DAP \< 60 mmHg, and vasoactive agents required); * Hyperkalemia , i.e. serum K+ levels \> 5.0 mEq/L; * Severe active bleeding; * Any other uncontrolled comorbidities that increase the risks associated with the study drug administration, as assessed by the medical expert team.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Time-to-clinical improvement | day 1 until day 28 | Time-to-clinical improvement (time from randomization to an improvement of two points (from the status at randomization) on a 7 category ordinal scale or live discharge from the hospital, whichever came first. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Critical or dead patients | day 1 until day 28 | Proportion of patients who will progress to critical illness/death |
| pO2/FiO2 ratio | day 1 until day 28 | Change in pO2/FiO2 ratio over time |
| SOFA score over time | day 1 until day 28 | Change Sequential organ failure assessment score (SOFA score) over time. The Score ranges from 0 to 24 (with 24 the worst)(PubMed ID: 11594901) |
| Responders | day 1 until day 28 | Rate of patients showing improvement of 2 points in 7 category ordinal scale (with 7 points the worst)(PubMed ID: 32187464) |
| Mechanical ventilation | day 1 until day 28 | Number of patients who require ventilation |
| Mechanical ventilation duration | day 1 until day 28 | Duration of ventilation (days) |
| Cardiovascular disease | day 1 until day 28 | Proportion of patients who develop arrhythmia, or myocardial infarction, or other cardiovascular disease not present at the baseline |
| Hospitalization | day 1 until day 28 | Duration of hospitalization in survivors (days) |
Countries
Italy
Contacts
Primary ContactGian Paolo Rossi, Prof.
Outcome results
None listed